Pulsatile inhibition of PI3K converts immune suppression by Tregs and M2-TAM to anti-tumor immune response in animal models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors

被引：1
|
作者：
Glaeske, Sarah [1 ]
Huebner, Franziska [1 ]
Anurin, Anna [1 ]
Janzer, Andreas [1 ]
Zitzmann-Kolbe, Sabine [1 ]
Paul, Juliane [1 ]
Glaeske, Katja [1 ]
Berndt, Sandra [1 ]
Mumberg, Dominik [1 ]
Gorjanacz, Matyas [1 ]
Ziegelbauer, Karl [1 ]
Kreft, Bertolt [1 ]
Liu, Ningshu [1 ]
机构：
[1] Bayer AG, Berlin, Germany
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-123
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dual inhibition of PI3K and PARP demonstrates synergistic anti-tumor activity in endometrioid endometrial cancer patient derived xenografts
    Hall, Tracilyn
    DiGloria, Celeste
    Kim, Minji
    Zhang, Ling
    Foster, Rosemary
    Growdon, Whitfield
    Rueda, Bo
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 398 - 398
  • [32] AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models
    Zhang, Nancy
    Caenepeel, Sean
    Wang, Ling
    Norman, Mark
    Kendall, Richard
    Burgess, Terri
    Radinsky, Robert
    Hughes, Paul
    Freeman, Daniel J.
    CANCER RESEARCH, 2012, 72
  • [33] Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
    Jeong, Yeong Gyu
    Katuwal, Nar Bahadur
    Kang, Min Sil
    Ghosh, Mithun
    Hong, Sa Deok
    Park, Seong Min
    Kim, Seul-Gi
    Kim, Tae Hoen
    Moon, Yong Wha
    CANCERS, 2023, 15 (19)
  • [34] Concurrent HER or PI3K inhibition potentiates the anti-tumor effect of ERK inhibitor BVD-523 (ulixertinib) in preclinical pancreatic cancer models
    Jiang, Hongmei
    Xu, Mai
    Li, Lin
    Highkin, Maureen
    Zhang, Daoxiang
    Li, Qiong
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    CANCER RESEARCH, 2018, 78 (13)
  • [35] The PI3K inhibitor GDC-0941 combines with trastuzumab for superior anti-tumor efficacy in HER2+breast cancer models
    De, P.
    Sun, Y.
    Carlson, J.
    Friedman, L.
    Dey, N.
    Leyland-Jones, B.
    CANCER RESEARCH, 2013, 73
  • [36] Anti-Tumor Activity for Novel Dual PI3K/BET Inhibitors, SF2523 and SF1126, in Ewing Sarcoma
    Goldin, A. N.
    Singh, A. R.
    Muldong, M.
    Joshi, S.
    Jamieson, C.
    Durden, D. L.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S76 - S76
  • [37] PI3K inhibition induces homologous repair defects in endometrioid endometrial cancer patient derived xenografts leading to synergistic anti-tumor activity with PARP inhibitors
    Rueda, Bo
    Digloria, Celeste
    Hall, Tracilyn
    Foster, Rosemary
    Borger, Darrell
    Growdon, Whitfield
    CANCER RESEARCH, 2015, 75
  • [38] Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
    Du, Yang
    Liu, Ye
    Wang, Di
    Bai, Hua
    Wang, Zhijie
    He, Xiran
    Zhang, Pei
    Tian, Jie
    Wang, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [39] TPX2 silencing exerts anti-tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway
    Huang, Dan-Hong
    Jian, Jie
    Li, Shuang
    Zhang, Yan
    Liu, Li-Zhen
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 44 (06) : 2113 - 2122
  • [40] Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer
    Zhang, Zhizhu
    Richmond, Ann
    Yan, Chi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
12345